A study published in the New England Journal of Medicine demonstrates that Science Corporation's PRIMA implant restores functional central vision in patients blinded by geographic atrophy (GA) caused by advanced age-related macular degeneration (AMD).[1] Post-implant patients were able to read letters, numbers and words for the first time after losing sight.[1] 80% of patients achieved a significant improvement in prosthetic visual acuity of at least logMAR 0.2 (10 ETDRS letters) at 12 months (p<0.001).[1] No deterioration of existing peripheral natural vision was observed.[1] The implant is safely placed under the atrophic macula, with most adverse events resolving within two months after surgery.[1] The Data Safety Monitoring Board (DSMB) concluded that the benefits of PRIMA outweigh the surgical risks and recommended the device for approval on the European market.[1] Unlike conventional therapies that only slow the progression of the disease, PRIMA directly restores lost functional vision.[1]